Education
About Us
Working with TipRanks
Follow Us
Illumina (ILMN)
NASDAQ:ILMN
ILMN Stock Chart & Stats
$128.96
-$1.43(-1.02%)
At close: 4:00 PM EST
$128.96
-$1.43(-1.02%)
Day’s Range― - ―
52-Week Range$68.70 - $153.06
Previous CloseN/A
Volume388.94K
Average Volume (3M)1.83M
Market Cap
$19.71B
Enterprise Value$15.42B
Total Cash (Recent Filing)$1.28B
Total Debt (Recent Filing)$2.58B
Price to Earnings (P/E)28.9
Beta1.35
Next Earnings
Feb 05, 2026EPS Estimate
1.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.34
Shares Outstanding152,800,000
10 Day Avg. Volume1,259,477
30 Day Avg. Volume1,828,483
Financial Highlights & Ratios
PEG Ratio-3.75
Price to Book (P/B)8.95
Price to Sales (P/S)4.86
P/FCF Ratio29.95
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue3.60
Enterprise Value/Gross Profit5.43
Enterprise Value/Ebitda11.91
Forecast
1Y Price Target
$117.25Price Target Upside-9.08% Downside
Rating ConsensusHold
Number of Analyst Covering12
EPS Forecast (FY)4.71
Revenue Forecast (FY)$4.29B
Bulls Say, Bears Say
Bulls Say
China Market RecoveryIllumina now expects $220 million in revenue from China in 2025, compared to prior guidance of $190-210 million.
Export Ban LiftThe lifting of the import ban on Illumina sequencers by China is viewed as a highly promising development that could enable Illumina to recapture a meaningful portion of lost revenue.
Revenue GrowthThe company's continued clinical growth and near-trough research performance is encouraging and bodes well for a return to high single-digit revenue growth over time.
Bears Say
Backlog ConversionOnly 77% of the current backlog is expected to convert to revenue in the next 12 months, which is the lowest level since 2020.
Sales DeclineSales in China have been declining significantly, with a ~20% year-on-year reduction outpacing declines seen by peers, highlighting challenges from local competition and procurement bias.
Unreliable Entities ListILMN still remains on the Unreliable Entities List, meaning instrument sales still require government approval.
Illumina News
ILMN FAQ
What was Illumina’s price range in the past 12 months?
Illumina lowest stock price was $68.70 and its highest was $153.06 in the past 12 months.
What is Illumina’s market cap?
Illumina’s market cap is $19.71B.
When is Illumina’s upcoming earnings report date?
Illumina’s upcoming earnings report date is Feb 05, 2026 which is in 59 days.
How were Illumina’s earnings last quarter?
Illumina released its earnings results on Oct 30, 2025. The company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.168 by $0.172.
Is Illumina overvalued?
According to Wall Street analysts Illumina’s price is currently Overvalued.
Does Illumina pay dividends?
Illumina does not currently pay dividends.
What is Illumina’s EPS estimate?
Illumina’s EPS estimate is 1.22.
How many shares outstanding does Illumina have?
Illumina has 152,800,000 shares outstanding.
What happened to Illumina’s price movement after its last earnings report?
Illumina reported an EPS of $1.34 in its last earnings report, beating expectations of $1.168. Following the earnings report the stock price went up 24.775%.
Which hedge fund is a major shareholder of Illumina?
Currently, no hedge funds are holding shares in ILMN
Illumina Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$117.25 (-9.08% Downside)
$117.25 (-9.08% Downside)
Blogger Sentiment
Bullish
ILMN Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 10.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $61.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.82%
12-Months-Change
Fundamentals
Return on Equity
31.20%
Trailing 12-Months
Asset Growth
2.71%
Trailing 12-Months
Company Description
Illumina
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
ILMN Company Deck
ILMN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical markets and the NovaSeq X transition, with revenue and earnings exceeding expectations. However, challenges in research markets and ongoing issues in China present hurdles. Despite these challenges, the company remains optimistic about its strategic initiatives and future growth.View all ILMN earnings summariesILMN Revenue Breakdown
72.16% Consumables
16.38% Service and other revenue
11.46% Instruments
ILMN Stock 12 Month Forecast
Average Price Target
$117.25
▼(-9.08% Downside)
Technical Analysis
Ownership Overview
2.79% Insiders
29.30% Mutual Funds
32.94% Other Institutional Investors
12.21% Public Companies and Individual Investors